Should I buy or sell Protagenic Therapeutics stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagenic Therapeutics in the last year. There are currently 1 buy rating...
What is Protagenic Therapeutics' stock price forecast for 2022?
1 Wall Street research analysts have issued 1-year price targets for Protagenic Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On...
How has Protagenic Therapeutics' stock price performed in 2022?
Protagenic Therapeutics' stock was trading at $1.3850 on January 1st, 2022. Since then, PTIX stock has decreased by 41.5% and is now trading at $0....
How were Protagenic Therapeutics' earnings last quarter?
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) announced its quarterly earnings results on Tuesday, November, 16th. The biotechnology company reporte...
Who are Protagenic Therapeutics' key executives?
Protagenic Therapeutics' management team includes the following people: Dr. Garo H. Armen Ph.D. , Co-Founder & Exec. Chairman (Age 69) Dr. Alexa...
Who are some of Protagenic Therapeutics' key competitors?
Some companies that are related to Protagenic Therapeutics include Research Solutions (RSSS) , Society Pass (SOPA) , Heritage Global (HGBL) , N...
What other stocks do shareholders of Protagenic Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Protagenic Therapeutics investors own include Fulcrum Ther...
What is Protagenic Therapeutics' stock symbol?
Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."
Who are Protagenic Therapeutics' major shareholders?
Protagenic Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Te...
About Protagenic Therapeutics
Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions
Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A.
